"World's Closest HIV Vaccine"
This is a U.S. news story, published by PBS, that relates primarily to Drugmaker Gilead news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsDrugmaker Gilead news
For more Drugmaker Gilead news, you can click here:
more Drugmaker Gilead newsNews about latin america economy
For more latin america economy news, you can click here:
more latin america economy newsPBS news
For more news from PBS, you can click here:
more news from PBSAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like this article about latin america economy, you might also like this article about
HIV prevention. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest high HIV rates news, previous HIV treatments news, news about latin america economy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
new HIV prevention toolsPBS
•A twice-yearly shot could help end AIDS, but only if it can get to everyone who needs it
72% Informative
Drugmaker Gilead says it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates.
But it has excluded nearly all of Latin America , where rates are far lower but increasing.
The drug called lenacapavir is already sold under the brand name Sunlenca to treat HIV infections in the U.S. , Canada , Europe and elsewhere.
Rising HIV rates among groups including gay men and transgender populations constitute “a public health emergency” in Latin America .
Sunlenca shots are about 80 percent to 90 percent effective in preventing HIV.
They cost about $1,500 a year in middle-income countries, beyond what most can afford to pay.
VR Score
79
Informative language
81
Neutral language
70
Article tone
formal
Language
English
Language complexity
54
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links